Actively Recruiting
Eye Safety Monitoring During TIVDAK Treatment for Recurrent or Metastatic Cervical Cancer
Led by Pfizer · Updated on 2026-10-13
100
Participants Needed
132
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying TIVDAK as a treatment option for patients with cervical cancer that has returned or spread after chemotherapy. The study aims to understand possible side effects of TIVDAK, especially those affecting the eyes. This is a phase 4 trial focusing on monitoring ocular safety in patients receiving this therapy. Participants will receive TIVDAK through an infusion into a vein every three weeks. Treatment continues until TIVDAK no longer works against the cancer. Eye exams are scheduled before treatment starts, before each of the first nine infusions, and then monthly for three months after stopping the drug to monitor any eye-related side effects. During the study, participants will have regular visits for eye assessments and clinical evaluations. Researchers will track the type, frequency, and severity of eye side effects up to 90 days after the last dose. They will also monitor serious adverse events, dose changes due to side effects, and the timing of eye issues. The study is expected to be completed by December 2028.
CONDITIONS
Brief Title
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here